Creating advanced human heart tissues using specialized heart cells
Engineering Human Heart Tissues with Polyploid Cardiomyocytes
['FUNDING_R01'] · DUKE UNIVERSITY · NIH-11070291
This study is working on creating more realistic human heart tissues from special stem cells to help us understand heart diseases better and develop new treatments, which could lead to improved care for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11070291 on ClinicalTrials.gov |
What this research studies
This research focuses on developing human heart tissues from induced pluripotent stem cells (hiPSCs) to better understand heart diseases and improve drug development. The team aims to enhance the maturity and functionality of these heart cells by engineering them to become polyploid, which is a characteristic of adult heart cells. By using advanced techniques like CRISPR and organ-on-chip systems, the research seeks to create more realistic models of the human heart for testing and therapeutic purposes. Patients may benefit from improved treatments and insights into heart conditions through this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit include individuals with genetic heart conditions or those interested in advancements in heart disease treatments.
Not a fit: Patients with acute heart failure or those requiring immediate clinical interventions may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for heart diseases and better drug testing methods.
How similar studies have performed: Previous research has shown promise in using engineered heart tissues for drug testing and disease modeling, indicating a potential for success in this novel approach.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BURSAC, NENAD — DUKE UNIVERSITY
- Study coordinator: BURSAC, NENAD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.